{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:14:33Z","timestamp":1791580473052,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.japh.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T15:48:33Z","timestamp":1686152913000},"page":"1495-1499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7690-7106","authenticated-orcid":false,"given":"Jennifer Athay","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3375-0895","authenticated-orcid":false,"given":"Nicole L.","family":"Chopski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2023.06.001_bib2","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.japh.2023.06.001_bib3","series-title":"To Help Providers Fight the Opioid Epidemic, \u201cX the X Waiver.\u201d Health Affairs ForeFront","author":"Berk","year":"2019"},{"key":"10.1016\/j.japh.2023.06.001_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/1060028016653608","article-title":"The Continuum of pharmacist prescriptive authority","volume":"50","author":"Adams","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.japh.2023.06.001_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1331\/154434506776180621","article-title":"Pharmacist involvement with immunizations: a decade of professional advancement","volume":"46","author":"Hogue","year":"2006","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2023.06.001_bib6","first-page":"175","article-title":"Pharmacy-based travel health services: state approaches to prescriptive authority","volume":"34","author":"Adams","year":"2018","journal-title":"J\u00a0Pharm Technol"},{"issue":"6","key":"10.1016\/j.japh.2023.06.001_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jac5.1794","article-title":"The over-regulation of pharmacist services: why over-the-counter naloxone should spark conversation about a \u201cstandard of care\u201d regulatory approach","volume":"6","author":"Adams","year":"2023","journal-title":"J Am Coll Clin Pharm"},{"issue":"6","key":"10.1016\/j.japh.2023.06.001_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ijpp.12488","article-title":"Pharmacy-based management of influenza: Lessons learned from research","volume":"26","author":"Klepser","year":"2018","journal-title":"Int J Pharm Pract"},{"issue":"4","key":"10.1016\/j.japh.2023.06.001_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PHH.0000000000000276","article-title":"Public health perceptions of community pharmacy partnership opportunities","volume":"21","author":"Roberts","year":"2015","journal-title":"J\u00a0Publ Health Manag Pract"},{"issue":"6","key":"10.1016\/j.japh.2023.06.001_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PHH.0000000000000482","article-title":"Potential for pharmacy-public health collaborations using pharmacy-based point-of-care testing services for infectious diseases","volume":"23","author":"Gubbins","year":"2017","journal-title":"J\u00a0Publ Health Manag Pract"},{"issue":"5","key":"10.1016\/j.japh.2023.06.001_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/PHH.0b013e31821138ae","article-title":"Extending the reach: local health department collaboration with community pharmacies in Palm Beach County, Florida for H1N1 influenza pandemic","volume":"17","author":"Rosenfeld","year":"2011","journal-title":"J\u00a0Public Health Manag Pract"},{"key":"10.1016\/j.japh.2023.06.001_bib14","article-title":"Nurse practitioners can increase treatment accessibility for opioid addiction","author":"Robinson","year":"2015","journal-title":"Health Affairs Forefront"},{"issue":"4","key":"10.1016\/j.japh.2023.06.001_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1060028020950193","article-title":"Pharmacists\u2019 patient care process: state \u201cscope of practice\u201d priorities for action","volume":"55","author":"Adams","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.japh.2023.06.001_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.7326\/M19-2403","article-title":"Growth and distribution of buprenorphine-waivered providers in the United States, 2007-2017","volume":"172","author":"McBain","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.japh.2023.06.001_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Q"},{"issue":"1","key":"10.1016\/j.japh.2023.06.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-3457","article-title":"Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality","volume":"171","author":"Beetham","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.japh.2023.06.001_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.japh.2023.06.001_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing Isn\u2019t Enough \u2013 pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2023.06.001_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.japh.2023.06.001_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder. X the X waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.japh.2023.06.001_bib25","author":"DiAmbrosio"},{"key":"10.1016\/j.japh.2023.06.001_bib26","author":"Tonko"},{"issue":"5","key":"10.1016\/j.japh.2023.06.001_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.japh.2023.06.001_bib30","author":"Holloran"},{"issue":"2","key":"10.1016\/j.japh.2023.06.001_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"7","key":"10.1016\/j.japh.2023.06.001_bib32","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the national drug abuse treatment clinical trials network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.japh.2023.06.001_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2208055","article-title":"Physician-delegated unobserved induction with buprenorphine in pharmacies","volume":"388","author":"Green","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2023.06.001_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.japh.2016.02.014","article-title":"Strategies to facilitate the implementation of collaborative practice agreements in chain community pharmacies","volume":"56","author":"Bacci","year":"2016","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2023.06.001_bib35","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v10i2.1389","article-title":"Pharmacists\u2019 patient care process: a state \u201cscope of practice\u201d perspective","volume":"10","author":"Adams","year":"2019","journal-title":"Innov Pharm"},{"issue":"4","key":"10.1016\/j.japh.2023.06.001_bib38","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.5688\/ajpe6577","article-title":"The Roles of pharmacy schools in bridging the gap between law and practice","volume":"82","author":"Adams","year":"2018","journal-title":"Am J Pharmaceut Educ"},{"issue":"9","key":"10.1016\/j.japh.2023.06.001_bib39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/jac5.1465","article-title":"Pharmacist scope of practice expansion: the virtue of forbearance","volume":"4","author":"Adams","year":"2021","journal-title":"Journal Am Coll Clin Pharm"},{"key":"10.1016\/j.japh.2023.06.001_bib43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/pharmacy8030112","article-title":"Pharmacist prescriptive authority: Lessons from idaho","volume":"8","author":"Adams","year":"2020","journal-title":"Pharmacy"},{"issue":"6","key":"10.1016\/j.japh.2023.06.001_bib44","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.1016\/j.japh.2020.07.013","article-title":"Rethinking pharmacy regulation: Core elements of idaho\u2019s transition to a \u201cstandard of care\u201d approach","volume":"60","author":"Adams","year":"2020","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"3","key":"10.1016\/j.japh.2023.06.001_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.japh.2017.12.015","article-title":"Pharmacist prescriptive authority for\u00a0tobacco cessation medications","volume":"58","author":"Adams","year":"2018","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2023.06.001_bib47","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.sapharm.2018.10.008","article-title":"Transitioning pharmacy to \u201cstandard of care\u201d regulation: Analyzing how pharmacy regulates relative to medicine and nursing","volume":"15","author":"Adams","year":"2018","journal-title":"Res Soc Adm Pharm"},{"issue":"1","key":"10.1016\/j.japh.2023.06.001_bib48","first-page":"109","article-title":"The standard of care: legal history and definitions: the bad and good news","volume":"12","author":"Moffett","year":"2011","journal-title":"West J Emerg Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123001681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123001681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:23Z","timestamp":1761544403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123001681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1544319123001681"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.06.001","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}